Roche takes the health and safety of our patients, customers, employees, and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more information, please visit www.roche.com or our ocrelizumab and COVID-19 FAQs.
COVID-19 FAQ web page updates are currently underway. In the meantime, please refer to the following PDF.
Prescribing information
Indications vary in different countries. The local prescribing information from your country is the primary source of information on the known and potential risks associated with ocrelizumab.